Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms

Bone Marrow Transplant. 2016 Apr;51(4):617-8. doi: 10.1038/bmt.2015.295. Epub 2016 Jan 4.

Authors

A Hanif¹, P N Hari², E Atallah³, K-S B Carlson³, M C Pasquini³, L C Michaelis³

Affiliations

¹ Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
² Department of Hematology and Oncology, Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA.
³ Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

PMID: 26726940
DOI: 10.1038/bmt.2015.295

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Allografts
Female
Hematologic Neoplasms / mortality*
Hematologic Neoplasms / therapy*
Hematopoietic Stem Cell Transplantation*
Humans
Male
Middle Aged
Nitriles
Primary Myelofibrosis / mortality*
Primary Myelofibrosis / therapy*
Pyrazoles / administration & dosage*
Pyrazoles / adverse effects
Pyrimidines

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib